Seaport Therapeutics, Inc. (SPTX)
Health Care · Biotechnology · NASDAQ
A clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neuropsychiatric and neurological conditions.
What Seaport Therapeutics, Inc. does
Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for neuropsychiatric and neurological disorders. The company leverages a proprietary platform to advance a pipeline of product candidates through preclinical and clinical development stages.
Themes: neuropsychiatric disorders, neurological diseases, biotech drug development
Fundamentals
- Price$19.73 as of 2026-10-21 close
- Market cap$1.1B as of 2026-07-27 (share count; price 2026-10-21)
- P/En/a earnings data not available
- ROICn/a No figure: its 10-K tags no operating income.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta0.20 as of 2026-09-02
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
Quarterly results
Balance sheet at 2026-06-30
- Cash and equivalents$64M
- Short-term investments$209M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Seaport Therapeutics, Inc. looks technically
Seaport Therapeutics, Inc. (SPTX): there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day low about 7 trading days ago. Trading volume is unusually light — only about 49% of its 30-day average.
Trend
7
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $21.64 | $21.64 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 17.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 52.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($15.79 to $20.13) — its "stochastic" reading is 91 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 90.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
7
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
|---|---|---|
| Since a 55-day breakout | it made a new 55-day low about 7 trading days ago | 7 sessions |
| All-time high | its highest closing price on record is $28.38 (set on 2026-08-27) | $28.38 |
| Given back of the 52-week move | not available for this company yet | n/a |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $14.85 (set on 2026-05-07) | $14.85 |
| Above the all-time low | it is 32.9% above its all-time low | +32.9% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 66th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.56 between its high and its low — about 7.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.56 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $15.80 and $21.26 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $15.80 – $18.53 – $21.26 |
| Typical daily range (% of price) | its price moves about 7.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.9% |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 49% of its 30-day average | 0.49× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 3.4% since the prior reading | -3.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.04 toward buy |
Candlestick patterns
1
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-21 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.1% |
|---|---|---|
| Gap filled | a 5.1% gap up opened on 2026-09-25 has been "filled" 17 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 17 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +10.91% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 6.5 percentage points (the stock lost 6.6% while the market lost 0.1%) | -6.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 9.4 percentage points (the stock lost 6.0% while the market gained 3.3%) | -9.4% |
| vs market, 6 months | not available for this company yet | n/a |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 1 of the 6 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 6 |
|---|---|---|
| Bearish technical signals | 2 of the 6 technical signals we can compute for it are currently in a bearish state: near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 6 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 15% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.3% of the share price. | -14.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% above the average price paid since 2026-05-01, so the typical buyer over that stretch is showing a gain. That average is $19.54 — a volume-weighted average of daily closes over 110 sessions, not a true tick-by-tick VWAP. | +1.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% below the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is under water. That average is $21.23 — a volume-weighted average of daily closes over 57 sessions, not a true tick-by-tick VWAP. | -7.1% |
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 50-day moving average · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · Analyst price target recently CUT · Most volatile (6%+ typical daily range) · At the top of its 14-day range (stochastic above 80) | Learn: adx · rsi · macd · breakout · volume and relative volume
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$37.00 range $28.00 – $50.00; median $35.00
Analyst estimates, as of 2026-10-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SPTX
- Consensus EPS estimate-$0.5566 next reporting period, as of 2026-10-19
- Estimate change, 30 days+$0.00944 from -$0.5661, on 2026-09-14, 35-day window
- Readings revised upward20% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial success and regulatory approval uncertainty.","Reliance on third-party vendors for manufacturing and clinical trial execution.","Need for additional financing to fund research, development, and operations."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 5 days since 2026-10-17 have not been checked yet.
- Last 180 days · read to 2026-10-172 buys ($20M) · 0 sells — 2 buying insiders
Most recent open-market transaction: 2026-06-22. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SPTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding SPTX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 1,797,251
- Reported value $39,036,292
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about SPTX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
SPTX had 3,649,879 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
SPTX had 6.82% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.92 days to cover at the same settlement.
- Reported short interest (shares) 3,649,879
- Short interest (% of shares outstanding) 6.82%
- Prior settlement (shares) 3,148,881
- Reported change 15.91%
- Days to cover (reported) 8.92
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Frequently asked questions
What does Seaport Therapeutics, Inc. (SPTX) do?
Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for neuropsychiatric and neurological disorders. The company leverages a proprietary platform to advance a pipeline of product candidates through preclinical and clinical development stages.
What sector is Seaport Therapeutics, Inc. (SPTX) in?
Seaport Therapeutics, Inc. (SPTX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Is Seaport Therapeutics, Inc. (SPTX) overbought or oversold right now?
Seaport Therapeutics, Inc. (SPTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SPTX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.